← Back to Screener
PharmaCyte Biotech, Inc. Common Stock (PMCB)
Price$0.76
Favorite Metrics
Price vs S&P 500 (26W)-35.89%
Price vs S&P 500 (4W)-3.41%
Market Capitalization$7.82M
P/E Ratio (Annual)0.26x
All Metrics
Book Value / Share (Quarterly)$3.67
P/TBV (Annual)0.17x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.45
Price vs S&P 500 (YTD)-3.50%
Gross Margin (TTM)81.70%
Net Profit Margin (TTM)-4184.21%
EPS (TTM)$-0.53
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-0.53
EPS (Annual)$4.18
ROI (Annual)59.08%
Gross Margin (Annual)0.00%
Net Profit Margin (5Y Avg)-4635.63%
Cash / Share (Quarterly)$1.91
P/E Normalized (Annual)0.26x
ROA (Last FY)55.57%
EBITD / Share (TTM)$-2.55
ROE (5Y Avg)-0.78%
Operating Margin (TTM)-3469.42%
Cash Flow / Share (Annual)$-0.44
P/B Ratio0.20x
P/B Ratio (Quarterly)0.21x
Net Income / Employee (Annual)$15
EV / Revenue (TTM)-309.36x
Net Interest Coverage (TTM)-1361.50x
ROA (TTM)-6.19%
EV / EBITDA (TTM)-6.96x
EPS Incl Extra (Annual)$4.18
Current Ratio (Annual)7.68x
Quick Ratio (Quarterly)12.24x
3-Month Avg Trading Volume0.33M
52-Week Price Return-36.64%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.53
P/S Ratio (Annual)782.20x
Asset Turnover (Annual)0.00x
52-Week High$1.51
Operating Margin (5Y Avg)-4103.67%
EPS Excl Extra (Annual)$4.18
Tangible BV CAGR (5Y)100.85%
26-Week Price Return-27.14%
Quick Ratio (Annual)7.60x
13-Week Price Return-20.37%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.33x
Enterprise Value$-12.344
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)10.54%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.33x
Pretax Margin (Annual)-16000.00%
Cash / Share (Annual)$2.72
3-Month Return Std Dev75.60%
Gross Margin (5Y Avg)37.52%
Net Income / Employee (TTM)$-2
ROE (Last FY)59.08%
Net Interest Coverage (Annual)-0.15x
EPS Basic Excl Extra (Annual)$4.18
Receivables Turnover (TTM)1.96x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.53
Receivables Turnover (Annual)26.00x
ROI (TTM)-7.66%
P/S Ratio (TTM)196.04x
Pretax Margin (5Y Avg)-4635.63%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.41
Price vs S&P 500 (52W)-71.74%
Year-to-Date Return0.64%
5-Day Price Return5.92%
EPS Normalized (Annual)$4.18
ROA (5Y Avg)-0.48%
Net Profit Margin (Annual)-16000.00%
Month-to-Date Return9.50%
Cash Flow / Share (TTM)$-0.21
EBITD / Share (Annual)$0.24
Operating Margin (Annual)-14500.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-0.78%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.53
P/TBV (Quarterly)0.22x
P/B Ratio (Annual)0.16x
Inventory Turnover (TTM)5.10x
Pretax Margin (TTM)-4184.21%
Book Value / Share (Annual)$7.64
Price vs S&P 500 (13W)-23.24%
Beta0.45x
Revenue / Share (TTM)$0.00
ROE (TTM)-7.66%
52-Week Low$0.63
Analyst Recommendations
Nov 2022
Dec 2022
Jan 2023
Feb 2023
2.17
2.17
2.17
2.17
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PMCBPharmaCyte Biotech, Inc. Common Stock | 196.04x | — | 81.70% | — | $0.76 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
PharmaCyte Biotech is a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box technology, which encapsulates live cells to deliver cancer-killing drugs directly at tumor sites. The platform is designed to protect therapeutic cells from the immune system while enabling localized drug delivery, with current development efforts focused on inoperable pancreatic cancer and other solid tumors. The company is leveraging this platform technology to address multiple cancer indications and diabetes.